Vascular endothelial growth factor (VEGF) undergoes alternative splicing to produce both proangiogenic and antiangiogenic isoforms. Preferential splicing of proangiogenic VEGF is determined by serine-arginine protein kinase 1 (SRPK1), which is upregulated in a number of cancers.
In the present study, we aimed to investigate SRPK1 expression in prostate cancer (PCa) and its association with cancer progression. SRPK1 expression was assessed using immunohistochemistry of PCa tissue extracted from radical prostatectomy specimens of 110 patients. SRPK1 expression was significantly higher in tumour compared with benign tissue (p
Journal of clinical pathology. 2015 Oct 23 [Epub ahead of print]
Nicholas Bullock, Jonathan Potts, Andrew J Simpkin, Anthony Koupparis, Steve J Harper, Jon Oxley, Sebastian Oltean
School of Physiology and Pharmacology, University of Bristol, Bristol, UK. , Department of Urology, Southmead Hospital, Bristol, UK. , School of Social and Community Medicine, University of Bristol, Bristol, UK. , Department of Urology, Southmead Hospital, Bristol, UK. , School of Physiology and Pharmacology, University of Bristol, Bristol, UK. , Department of Cellular Pathology, Southmead Hospital, Bristol, UK. , School of Physiology and Pharmacology, University of Bristol, Bristol, UK.